Literature DB >> 10555898

Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation.

F Khan1, J J Belch.   

Abstract

OBJECTIVE: To measure skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in the digits of patients with systemic sclerosis (SSc) and control subjects. Additionally, to test the effects of oral L-arginine supplementation versus placebo in patients.
METHODS: Skin blood flow was measured at the dorsum of the finger using laser Doppler flowmetry during iontophoresis of endothelium dependent (acetylcholine) and independent (sodium nitroprusside) vasodilators. L-arginine and placebo supplementation were given in a double blind, crossover fashion (8 g daily for 28 days).
RESULTS: In comparison to control subjects, dose dependent vascular responses to acetylcholine were diminished in patients with SSc (1.7 +/- 0.3, 3.6 +/- 0.7, 5.9 +/- 1.5 vs 1.4 +/- 0.1, 2.4 +/- 0.6, 2.4 /- 0.5; p < 0.01, ANOVA). Vascular responses to sodium nitroprusside were not significantly different between control subjects and SSc patients. L-arginine supplementation, however, had no significant effect on vascular responses to acetylcholine and sodium nitroprusside.
CONCLUSION: There is an abnormality of endothelial dependent vasodilatation in the digital vasculature of patients with SSc. The lack of effect of supplementation with L-arginine suggests the abnormality may be independent of the L-arginine/nitric oxide pathway and may involve prostanoids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555898

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.

Authors:  Christopher M Rembold; Carlos R Ayers
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

2.  "Beet" the cold: beetroot juice supplementation improves peripheral blood flow, endothelial function, and anti-inflammatory status in individuals with Raynaud's phenomenon.

Authors:  Anthony I Shepherd; Joseph T Costello; Stephen J Bailey; Nicolette Bishop; Alex J Wadley; Steven Young-Min; Mark Gilchrist; Harry Mayes; Danny White; Paul Gorczynski; Zoe L Saynor; Heather Massey; Clare M Eglin
Journal:  J Appl Physiol (1985)       Date:  2019-07-25

Review 3.  Complementary therapies for patients with systemic sclerosis.

Authors:  Kimberly Showalter; Aileen Hoffmann; Nicole DeCredico; Anjali Thakrar; Esperanza Arroyo; Isaac Goldberg; Monique Hinchcliff
Journal:  J Scleroderma Relat Disord       Date:  2019-03-29

Review 4.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

5.  Treatment of Raynaud's phenomenon: new insights and developments.

Authors:  Ariane L Herrick
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

6.  Vascular involvement in systemic sclerosis (scleroderma).

Authors:  Debendra Pattanaik; Monica Brown; Arnold E Postlethwaite
Journal:  J Inflamm Res       Date:  2011-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.